BioNTech (BNTX)
(Delayed Data from NSDQ)
$111.77 USD
-2.70 (-2.36%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $111.72 -0.05 (-0.04%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$111.77 USD
-2.70 (-2.36%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $111.72 -0.05 (-0.04%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth D Momentum C VGM
Zacks News
BioNTech (BNTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
BioNTech's (BNTX) fourth-quarter COVID-19 vaccine sales are likely to have declined with the pandemic largely in control. Updates on the company's booster dose authorization status and pipeline will be in focus.
BioNTech SE Sponsored ADR (BNTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
BioNTech SE Sponsored ADR (BNTX) closed at $131.54 in the latest trading session, marking a +0.59% move from the prior day.
BioNTech SE Sponsored ADR (BNTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $130.86, marking a -1.84% move from the previous day.
BioNTech SE Sponsored ADR (BNTX) Stock Moves -0.79%: What You Should Know
by Zacks Equity Research
BioNTech SE Sponsored ADR (BNTX) closed at $137.53 in the latest trading session, marking a -0.79% move from the prior day.
BioNTech SE Sponsored ADR (BNTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
BioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $143.92, moving +0.64% from the previous trading session.
BioNTech SE Sponsored ADR (BNTX) Stock Moves -0.68%: What You Should Know
by Zacks Equity Research
In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $141.15, marking a -0.68% move from the previous day.
Implied Volatility Surging for BioNTech (BNTX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to BioNTech (BNTX) stock based on the movements in the options market lately.
BioNTech SE Sponsored ADR (BNTX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
BioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $144.40, moving +0.94% from the previous trading session.
Pfizer (PFE) Q4 Earnings Top, 2023 View Disappoints, Stock Down
by Zacks Equity Research
Pfizer (PFE) beats estimates for Q4 earnings and sales. Its 2023 financial outlook falls short of expectations. Stock down in pre-market trading.
The Zacks Analyst Blog Highlights Pfizer/BioNTech, Moderna and Novavax
by Zacks Equity Research
Pfizer/BioNTech, Moderna and Novavax are included in this Analyst Blog.
Novavax (NVAX) COVID Jab Aids Growth, Overdependence a Challenge (revised)
by Zacks Equity Research
Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.
FDA Panel Endorses Simplification of COVID-19 Vaccine Strategy
by Zacks Equity Research
An FDA advisory committee unanimously votes in favor of using the same COVID-19 vaccine strain composition for primary series and booster doses.
Can Pfizer (PFE) Beat Expectations This Earnings Season?
by Zacks Equity Research
Higher alliance revenues from Eliquis, higher sales of Prevnar vaccines and drugs like Vyndaqel/Vyndamax are likely to have contributed to Pfizer's (PFE) sales growth in Q4.
Novavax (NVAX) COVID Jab Aids Growth, Overdependence A Woe
by Zacks Equity Research
Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.
Novavax (NVAX) Gets Nod for COVID-19 Booster Jab in South Korea
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine gets approval in South Korea as a booster dose in adults 18 years and older.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Novavax (NVAX) Names John Jacobs as New CEO, Shares Rise
by Zacks Equity Research
Novavax (NVAX) appoints John C. Jacobs as its new president and chief executive officer, effective Jan 23, 2023.
Novavax (NVAX) Starts A New Study on COVID-Flu Combo Jab
by Zacks Equity Research
Novavax (NVAX) initiates a mid-stage study evaluating its COVID-19-Influenza combination and standalone influenza vaccines in adults aged 50 through 80 years.
Are Investors Undervaluing BioNTech (BNTX) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 Big Drug, Biotech Stocks to Boost Your Portfolio in 2023
by Kinjel Shah
Here we discuss three big drug and biotech companies, Sanofi (SNY), GSK (GSK) and BioNTech (BNTX), which may prove to be good bets for your portfolio next year.
Moderna's (MRNA) BA.1 Omicron Booster Gets CHMP Nod for Kids
by Zacks Equity Research
The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.1 subvariant, for young children aged between six and 11 years.
FDA Delays Decision on AstraZeneca (AZN), Merck's Lynparza sNDA
by Zacks Equity Research
The FDA extends the review period of AstraZeneca (AZN)/Merck's filing seeking label expansion for Lynparza's indication in prostate cancer. The FDA intends to use this time to review the submission.
Icosavax (ICVX) Up 112% on Upbeat Data From RSV Jab Study
by Zacks Equity Research
Data from an early-stage study showed that Icosavax's (ICVX) investigational RSV vaccine exhibited sustained immunologic response following six months of dose administration.
Wave Life Sciences (WVE) Up 26% on Collaboration With GSK
by Zacks Equity Research
Wave Lifesciences (WVE) signs a four-year research collaboration with GSK to advance discovery and development of oligonucleotide therapeutics focusing on novel genetic targets
Eli Lilly (LLY) 2023 Guidance Falls Short, Stock Declines
by Zacks Equity Research
Eli Lilly's (LLY) 2023 EPS guidance falls short of the Zacks Consensus Estimates and our model estimates. The company plans to launch four new drugs next year.